EFFECT

SEC Filing Details

Document Details

Form

EFFECT

Filing Date

Oct 1, 2021

Document Date

Oct 1, 2021

Form Description

EFFECT

Filing Group

Other

Company

Akari Therapeutics

Issuer

AKARI THERAPEUTICS PLC

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Akari TX

EFFECT

SEC Filing Details

Document Details

Filing Formats

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Skip links

EFFECT

SEC Filing Details

Document Details

Filing Formats

Footer

LONDON

NEW YORK

EXPANDED ACCESS POLICY